Lifitegrast 5% Ophthalmic Solution and Contact Lens Dryness

Contact Lens Clinical Trial

Official title:

Safety and Efficacy of Lifitegrast 5% Ophthalmic Solution in Contact Lens Discomfort

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03686878
• Other study ID #: LF5-CLD
• Status: Completed
• Phase: Phase 4
• Start date: December 16, 2016
• Est. completion date: July 14, 2017

Study information

• Verified date: September 2018
• Source: EV Clinical Trials
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The most common reason for contact lens discontinuation is contact lens discomfort. The investigators believe that inflammation plays a role in contact lens discomfort and the use of lifitegrast 5% ophthalmic solution may reduce end of the day contact lens discomfort. This study will enroll 21 contact lens users who will be receiving lifitegrast 5% ophthalmic solution and monitor the contact lens discomfort for a 8 week period while.

Description:

Contact lens discontinuation is mostly associated with ocular discomfort. Most patients identifying dryness as the primary reason for contact lens discontinuation. Patients often resort to contact lens solutions, lubricating and/or rewetting drops to temporality improve their contact lens wearing experience. Clinicians often resort to changing contact lens designs, solutions and wearing modalities to improve comfort.

Contact lens discomfort is believed to be mediated by many factors including inflammation and very similar in clinical symptoms of dry eye disease and symptoms of dryness.

Lifitegrast 5.0% ophthalmic solution is an FDA approved solution for the management of signs and symptoms of dryness of dry eye disease. Studies have shown lifitegrast 5% ophthalmic solution may work by blocking the interaction between ICAM-1 and LFA-1 leading to a decrease in activation and recruitment of T-cells, an initial step in inflammation.

The safety and efficacy of Xiidra has been studied in four, 12 week clinical trials involving over 2,100 patients for signs (https://www.xiidra-ecp.com/efficacy-treating-signs) and symptoms (https://www.xiidra-ecp.com/efficacy-symptom-improvement).

The purpose of this open label, interventional study is to examine the effect of lifitegrast 5% ophthalmic solution in contact lens wearing experience by using the CLDEQ-8.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: July 14, 2017
• Est. primary completion date: July 14, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

1. Agree with study protocol

2. Provide Informed Consent

3. Age 21 or over

4. Previous 10 months history of self-assessed comfortable wear samfilcon A contact lenses

Exclusion Criteria:

1. Unable or unwilling to comply with study protocol

2. Unable of unwilling to provide Informed consent

3. Self-reported symptomatic intolerance of contact lenses

4. History of an active anterior segment, eyelids, eyelashes, corneal or conjunctival pathology, ongoing ocular infection, inflammation or any other ocular problem that would require management with additional topical ophthalmic medications.

5. Have had a history of corneal surgery (corneal transplants, LASIK, PRK).

Related Conditions & MeSH terms

• Contact Lens
• Contact Lens Discomfort
• Contact Lens Dryness

Intervention

Drug:
• Lifitegrast
Lifitegrast used twice a day

Locations

Country	Name	City	State
United States	Eye & Vision	Richardson	Texas

Sponsors (1)

Lead Sponsor	Collaborator
EV Clinical Trials

Country where clinical trial is conducted

United States, 

References & Publications (3)

Efron N. Contact lens wear is intrinsically inflammatory. Clin Exp Optom. 2017 Jan;100(1):3-19. doi: 10.1111/cxo.12487. Epub 2016 Nov 2. Review. — View Citation

Godin MR, Gupta PK. Lifitegrast ophthalmic solution in the treatment of signs and symptoms of dry eye disease: design, development, and place in therapy. Clin Ophthalmol. 2017 May 22;11:951-957. doi: 10.2147/OPTH.S117188. eCollection 2017. Review. — View Citation

Nichols JJ, Willcox MD, Bron AJ, Belmonte C, Ciolino JB, Craig JP, Dogru M, Foulks GN, Jones L, Nelson JD, Nichols KK, Purslow C, Schaumberg DA, Stapleton F, Sullivan DA; members of the TFOS International Workshop on Contact Lens Discomfort. The TFOS International Workshop on Contact Lens Discomfort: executive summary. Invest Ophthalmol Vis Sci. 2013 Oct 18;54(11):TFOS7-TFOS13. doi: 10.1167/iovs.13-13212. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in CLDEQ-8 scores as reported by study participants	measured changes in CLDEQ-8 scores as reported by study participants	baseline to week 8
Primary	Lisamine (corneal, conjunctiva) staining scores	Lisamine score using the Oxford-Schema scoring	baseline to week 8
Secondary	Visual Acuity	Best corrected visual acuity measured by Snellen chart	Baseline to week 8